{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-21-000061","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2021-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.539473+00:00","generated_at":"2026-06-30T00:02:32.145060+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant receives $200M investment from Roivant at 15% premium to VWAP","bullets":["Roivant purchases 17,021,276 shares at $11.75/share ($200M gross proceeds), a 15% premium to 20-day VWAP.","Roivant's ownership increases from 57.5% to 63.8%; Immunovant pro forma cash ~$600M.","Proceeds to fund development of IMVT-1401; pivotal trial for myasthenia gravis planned within 12 months.","Dr. Frank Torti appointed Executive Chairperson, effective immediately, no additional compensation.","Investment approved by special committee of independent directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-21-000061","json":"https://secwatch.observer/filing/0001764013-21-000061.json","markdown":"https://secwatch.observer/filing/0001764013-21-000061.md","text":"https://secwatch.observer/filing/0001764013-21-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000061/0001764013-21-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000061/imvt-20210802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:02:32.145060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abbd86a1a4","claim":"Dr. Frank M. Torti was appointed as Executive Chairperson at Immunovant, Inc..","evidence_excerpt":"Effective August 2, 2021, Dr. Frank M. Torti, age 42, Immunovant’s current Chairperson, was appointed Executive Chairperson.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000061/0001764013-21-000061-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairperson"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}